Patents by Inventor Jeff A. Zablocki

Jeff A. Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABCA1 elevating compounds
    Patent number: 7579504
    Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: August 25, 2009
    Assignee: Gilead Sciences, Inc.
    Inventors: Dmitry Koltun, Melanie Boze, Jeff Zablocki
  • ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION
    Publication number: 20090209533
    Abstract: Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Inventors: Jeff Zablocki, Matthew Abelman, Michael Organ, Yaroslav Bilokin, Elfatih Elzein, Tetsuya Kobayashi, Rao Kalla, Thao Perry, Xiaofen Li, Robert Jiang, Ivan Diamond, Lina Yao, Peidong Fan, Maria Pia Arolfo, Zhan Jiang, Wing Ming Keung, Guoxin Tao
  • Substituted heterocyclic compounds
    Patent number: 7566717
    Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    Type: Grant
    Filed: July 9, 2008
    Date of Patent: July 28, 2009
    Assignee: Gilead Sciences, Inc.
    Inventors: Venkata Palle, Jeff Zablocki
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20090181986
    Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 8, 2009
    Publication date: July 16, 2009
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
  • C-pyrazole A2A receptor agonists
    Patent number: 7553823
    Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: June 30, 2009
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • A1 ADENOSINE RECEPTOR AGONISTS
    Publication number: 20090156544
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Application
    Filed: February 23, 2009
    Publication date: June 18, 2009
    Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
  • A1 ADENOSINE RECEPTOR AGONISTS
    Publication number: 20090137520
    Abstract: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.
    Type: Application
    Filed: February 3, 2009
    Publication date: May 28, 2009
    Inventors: Elfatih Elzein, Xiaofen Li, Jeff Zablocki
  • A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20090137802
    Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    Type: Application
    Filed: January 28, 2009
    Publication date: May 28, 2009
    Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
  • 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
    Publication number: 20090105283
    Abstract: The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
    Type: Application
    Filed: October 15, 2008
    Publication date: April 23, 2009
    Inventors: Dmitry Koltun, Eric Parkhill, Melanie Boze, Jeff Zablocki, Natalya Vasilevich, Elena Mayboroda, Andrei Glushkov, Andrew G. Cole, Jeffrey Chisholm
  • Aadenosine receptor antagonists
    Patent number: 7521554
    Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: April 21, 2009
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
  • A3 ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20090099212
    Abstract: Disclosed are novel methods of antagonizing the A3 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R is hydrogen or acyl; R1 is hydrogen, halo, optionally substituted C1-4 alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl; R2 is optionally substituted C1-4 alkyl; Y is C1-4 alkylene; and Z is phenyl, optionally substituted with halo, optionally substituted C1-4 alkyl, or C1-4 alkoxy. The A3 adenosine receptors may be antagonized in order to treat a disease state is chosen from renal failure, nephritis, hypertension, oedemas, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, asthma, respiratory disorders, ischemia-induced injury of the brain, heart and kidney, and diarrhea.
    Type: Application
    Filed: October 16, 2008
    Publication date: April 16, 2009
    Inventors: Jeff Zablocki, Rao Kalla, Dewan Zeng
  • A adenosine receptor agonists
    Patent number: 7514417
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: April 7, 2009
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
  • Aadenosine receptor agonists
    Patent number: 7488720
    Abstract: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: February 10, 2009
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Xiaofen Li, Jeff Zablocki
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20090012103
    Abstract: The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 8, 2009
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki
  • A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20080318983
    Abstract: Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A2B adenosine receptor antagonists having the structure of Formula I or Formula II:
    Type: Application
    Filed: June 26, 2008
    Publication date: December 25, 2008
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki, Dewan Zeng, Hongyan Zhong
  • ABCA1 ELEVATING COMPOUNDS
    Publication number: 20080293757
    Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 6, 2008
    Publication date: November 27, 2008
    Inventors: Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
  • Substituted heterocyclic compounds
    Patent number: 7452889
    Abstract: Disclosed are novel substituted heterocyclic derivatives having the structure of Formula I: The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, diabetes, and myocardial infarction.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: November 18, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Kenneth Rehder, Jeff Zablocki
  • Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as Aadenosine receptor antagonists
    Patent number: 7449473
    Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure: wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: November 11, 2008
    Assignee: CV Therapeutics, Inc.
    Inventors: Rao Kalla, Elfatih Elzein, Tim Marquart, Thao Perry, Xiaofen Li, Jeff Zablocki
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20080275238
    Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    Type: Application
    Filed: July 9, 2008
    Publication date: November 6, 2008
    Inventors: Venkata Palle, Jeff Zablocki
  • Bicyclic Nitrogen-containing Heterocyclic compounds for use as Stearoyl CoA Desaturase inhibitors
    Publication number: 20080255130
    Abstract: The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like.
    Type: Application
    Filed: April 9, 2008
    Publication date: October 16, 2008
    Inventors: Dmitry Koltun, Jeff Zablocki, Eric Parkhill, Andrei Glushkov, Natalya Vasilevich, Timur Zilbershtein, Alexey Ivanov, Jeffrey Chisholm